MaxQ Medical Secured $31.5 Million Series A Funding

The Sunnyvale-based company will use the capital to advance its prostate care ultrasound platform.

Updated on Oct. 14, 2026 in Healthcare

MaxQ Medical Secured $31.5 Million Series A Funding

Live Poll

Do you believe recent advancements in medical technology are effectively improving healthcare options for patients?

MaxQ Medical has closed a $31.5 million Series A funding round to accelerate the development of its specialized transurethral prostate care system. The company uses miniaturized ultrasound transducers developed by Fraunhofer IPMS to combine imaging and therapy.

Why it matters

The integration of compact ultrasound technology into medical instruments is essential for advancing minimally invasive treatments for benign prostatic hyperplasia. This capital allows the firm to move forward with its clinical program and future medical applications.

MaxQ Medical secured $31.5 million in its recent Series A funding round. The firm is currently developing a proprietary transurethral system designed to treat benign prostatic hyperplasia.

The players

MaxQ Medical

This Sunnyvale-based startup is a spinout of Orchard Ultrasound Innovation and specializes in developing transurethral medical systems.

Fraunhofer IPMS

This research organization specializes in integrating micromechanics and semiconductor technology to manufacture miniaturized ultrasound transducers.

Orchard Ultrasound Innovation

Based in Sunnyvale, this organization serves as the parent entity and incubator for the technology now being commercialized by MaxQ Medical.

The details

MaxQ Medical, a spinout of the Sunnyvale-based Orchard Ultrasound Innovation, utilizes CMUT technology to convert electrical signals into ultrasound. This miniaturized hardware allows for the creation of compact, multi-channel ultrasonic systems integrated directly into surgical instruments.

October 14, 2026: The funding news was finalized.

Market Landscape

The adoption of CMUT technology represents a departure from bulky, traditional piezoelectric ultrasound systems toward highly integrated, compact medical devices. This shift positions the company at the forefront of the move to miniaturize complex surgical tools.

Patients may eventually see a shift in the availability of less invasive options for treating benign prostatic hyperplasia as this system moves through clinical development. For the time being, there is no direct impact on current surgical pricing or availability at local clinics.

The takeaway

The move toward integrating imaging and therapy in a single instrument highlights the growing efficiency of miniaturized medical components. Advancements in semiconductor-based transducers are likely to enable smaller, more effective diagnostic and therapeutic tools in the coming years.